Compare Amgen, Inc. (AMGN) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs C.H. Robinson Worldwide, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while C.H. Robinson Worldwide, Inc. trades at $193.45 (market cap $22.81B). The key difference: Amgen, Inc. is far larger — about 8.6× C.H. Robinson Worldwide, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CHRW | |
|---|---|---|
Market Cap | $196.12B | $22.81B |
Sector | Health | Industrials |
52-Week High | $388.16 | $200.59 |
52-Week Low | $271.18 | $96.82 |
Enterprise Value | $241.41B | $24.29B |
Dividend Yield | 2.77% | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CHRW trades at $193.5, up 0.38% today, with a bullish technical signal from moving averages and a consensus analyst price target of $199.25. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.35 surpassing the $1.23 estimate. The company maintains strong profitability with a 34.84% ROE and recently acquired DeSpir Logistics to enhance high-value cargo capabilities, signaling strategic growth initiatives.
The outlook is positive, supported by earnings momentum and operational efficiency, but risks include a high P/E ratio of 39.17 suggesting premium valuation, exposure to freight market cyclicality, and competitive pressures in the logistics sector. Upside potential hinges on continued execution and industry recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
